
Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …

Gilead Sciences has today announced 96-week results from two Phase III studies evaluating its investigational once-daily single tablet regimen (STR), …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

